The mission of the NINDS Division of Translational Research (DTR) is to accelerate basic research findings towards patient use for neurological disorders and stroke by providing funding, expertise, and resources to the research community.
DTR provides funding and resources (approximately $100 million annually) through grants, cooperative agreements, and contracts to academic and industry researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships).
DTR offers a variety of programs that support the design, implementation, and management of research activities critical to translational challenges in the treatment of neurological disease.
For investigators and potential investors interested in our active grant portfolio or in partnering.
An overview of the public health impact the Grantees have had for research on brain and nervous system disorders.
The NINDS Biomarker Program supports analytical and clinical validation of candidate biomarkers for neurological disease.
A suite of funding opportunity announcements to enable grantees to build on their innovative basic science findings and initiate preclinical drug discovery and development.
The Preclinical Screening Platform for Pain (PSPP) will establish a preclinical testing platform to test potential non-addictive treatments (small molecules, biologics, or natural products) for acute and/or chronic pain.
Resources for compound-screening service to identify candidate therapeutics to ameliorate the epilepsies. Current efforts emphasize unmet medical needs in epilepsy, including treatments for refractory epilepsies, epileptogenesis, and disease progression.
Cooperative agreement and SBIR Fast-Track award programs support small molecule drug discovery and development. These programs are designed to maintain the grantees’ intellectual property while providing non-dilutive funding.
Cooperative Agreement and SBIR Fast-Track award programs support discovery and development of biotechnology product- and biologics-based therapies. These programs are designed to maintain the grantees’ intellectual property while providing non-dilutive funding.
Cooperative agreement and SBIR Fast-Track award programs support the discovery and development of therapeutic Biotechnology Products and Biologics (e.g. peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.
The The HEAL Pain Therapeutics Development Program (PTDP) is part of the Helping to End Addiction Long-term® (HEAL) Initiative, a trans-NIH research effort focused on improving prevention and treatment for opioid misuse and addiction and enhancing pain management.
Funding to support development, validation and verification, and early clinical studies of therapeutic devices to treat neurological disorders.
The URGenT program will provide funding and resources to advance gene-based therapies for ultra-rare neurological disorder from late-stage pre-clinical development into clinical testing.
Funding program to allow small business concerns to conduct innovative neuroscience research at different stages of development, including applied bench research, translational research, and early-stage clinical trials.
The Neural Exposome and Toxicology programs support research and provide resources for internal and external exposures that affect the brain and nervous system health, exposures to chemical threats and the development of countermeasures, Drug Safety Evaluations, and overall safety of NIH-funded research including biohazards, Select Agents, and Dual Use Research of Concern.
The mission of the NIH CounterACT Program is to understand fundamental mechanisms of toxicity caused by chemical threat agents and the application of this knowledge to develop promising therapeutics for reducing mortality and morbidity caused by these agents. CounterACT is a trans-NIH effort lead by NINDS which funds small and large grants, supportive contract facilities, and interagency agreements with the Department of Defense.
Short course to introduce academic researchers to the principles of neurotherapeutic drug discovery and development. Participants who have attended the short course program will have ongoing access to senior faculty who will assist the trainee to achieve success in their individual drug development projects.